Organization · Venture Capital
Main Sequence
Main Sequence is a venture capital firm based in Australia, focusing on deep technology investments that address significant global challenges. Established by CSIRO, it bridges the gap between research and industry, managing over $1 billion in capital.
Overview
What Main Sequence does
What Main Sequence is
Main Sequence is a venture capital firm based in Australia, focusing on deep technology investments that address significant global challenges. Established by CSIRO, it bridges the gap between research and industry, managing over $1 billion in capital.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2017
- Approximate age
- About 9 years
- Structured capabilities
- Funder
- Last reviewed
- March 18, 2026
Official channels
Find Main Sequence elsewhere
Open the official website or a supported primary organization account.
Capability profile
Main Sequence as a funder
Investment thesis
Main Sequence invests in deep technology companies that address significant global challenges, bridging the gap between research and industry.
Focus narrative
Main Sequence focuses on deep technology companies that address significant global challenges, investing from seed to Series B stages. The firm targets sectors such as space, healthcare, industrial productivity, and sustainable agriculture, with a commitment to supporting innovations that tackle issues like decarbonization, food security, and advanced intelligence.
Value beyond capital
Main Sequence adds value by leveraging its connections with CSIRO and 28 Australian universities to bridge the gap between research and commercialization, providing strategic support and resources to portfolio companies.
Terms and economics
- Typical check
- $1,000,000–$450,000,000
- Sweet spot
- $10,000,000
Focus and fit
- Stages
- Seed · Series A · Series B
- Sectors
- Artificial IntelligenceHealthcareClimate & SustainabilitySpace TechIndustrial & ManufacturingAgTech
- Regions
- Global
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 51
Portfolio context
Notable portfolio companies include: Terria, which develops advanced mapping and digital twin technologies; Loam Bio, focusing on microbial technology for carbon capture in agricultural soils; Cauldron, Asia-Pacific’s first manufacturing launchpad for precision fermentation; Coviu, innovating in telehealth solutions; Regrow, providing scalable and sustainable crop insights; Breaker, utilizing AI to optimize robotics deployment; and Cylite, which achieved a material return for investors through advancements in eye health.
Common questions
What to know about Main Sequence
Upseed classifies Main Sequence under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 18, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.